Know Cancer

or
forgot password

DAHANCA 24: Prognostic Value of 18F-FAZA Positron Emission Tomography After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck


N/A
18 Years
N/A
Not Enrolling
Both
Cancer of the Head and Neck

Thank you

Trial Information

DAHANCA 24: Prognostic Value of 18F-FAZA Positron Emission Tomography After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck


Inclusion Criteria:



- Histological proven squamous cell carcinoma of the pharynx, larynx, oropharynx and
hypopharynx

- Curative intent and no prior treatment

- Age >= 18 years

- stage T1-4 N0-N3 M0.

- Informed consent according to local guidelines and national law

- The patient is able (psychological, sociological, geographical and physical) to carry
through the treatment and follow-up

- Fertile women must use contraceptive devices (IUD or oral contraceptives)

Exclusion Criteria:

- No serious concurrent medical disease

- No metastasis

- No prior disease that can affect the treatment, evaluation or outcome of current
disease

- No pregnant or breastfeeding woman

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Can 18F-FAZA can be used as a prognostic marker in HNSCC?

Outcome Time Frame:

1, 5 years

Safety Issue:

No

Principal Investigator

Jens Overgaard, Prof., MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Danish Head and Neck Cancer Group (DAHANCA)

Authority:

Denmark: The Danish National Committee on Biomedical Research Ethics

Study ID:

DAHANCA 24

NCT ID:

NCT01017224

Start Date:

November 2009

Completion Date:

May 2012

Related Keywords:

  • Cancer of the Head and Neck
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms

Name

Location